A phase II trial of ZD1839 (Iressa) [gefitinib] in patients with nonresectable adrenocortical carcinoma (ACC)
Phase of Trial: Phase II
Latest Information Update: 24 May 2018
At a glance
- Drugs Gefitinib (Primary)
- Indications Adrenal cancer
- Focus Therapeutic Use
- 13 Aug 2008 Actual completion date identified as January 2007, as reported by ClinicalTrials.gov.
- 13 Aug 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
- 06 Nov 2005 New trial record.